EyePoint Announces Proposed Public Offering of Common Stock

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has initiated a public offering of $150 million in common stock to support its clinical development and corporate initiatives [1][3]. Group 1: Offering Details - The public offering consists of $150 million in shares, with an option for underwriters to purchase an additional $22.5 million within 30 days [1][2]. - J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are the joint book running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as to support earlier stage pipeline initiatives and general corporate purposes [3]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, with its lead product candidate being DURAVYU™, which is currently in Phase 3 trials [7]. - DURAVYU™ combines vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E™ technology [7]. - The company has a history of developing four approved drugs over three decades, treating tens of thousands of patients [8].